Gold Prices Hold Near $4,400 as Fed Rate Hike Bets Ease 
Oil Prices Slip as Trump Eases Iran Supply Fears 
JPMorgan Sees ECB Raising Rates to 2.75% in December 
FTSE 100 Falls as US-Iran Conflict Drives Oil Prices Higher 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
China Services PMI Beats Forecasts as Domestic Demand Improves 
Singapore Straits Times Index Hits Record High as Banks, Property Stocks Rally 
Iran’s Hormuz Oil Pressure Fades as Gulf Crude Flows Continue 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
European Stocks Edge Higher as Bond Yields Ease 
Uranium Prices Could Top $100 as Nuclear Demand Grows 
Asian Currencies Rise as Yen Surges on Fed Rate Outlook 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Hong Kong Eyes Offshore Yuan Expansion, Deeper China Market Links 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Add as a preferred source on Google
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
